EW

Edwards Lifesciences (EW) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.

Earnings

Edwards CEO Says TAVR Growth Now Hinges On Market, Not Share: 'I'm Signaling Confidence'

Edwards raised its full-year TAVR growth outlook to 9% to 9.5% while saying rival-share gains have leveled off.

Earnings

Edwards Lifesciences Lifts 2026 Sales Growth Forecast To About 11.5% On 10.5% Third-Quarter Gain

The heart valve maker also raised its aortic, mitral-tricuspid and adjusted earnings outlooks after sales reached $1.72 billion.